James W Welsh

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer
    James W Welsh
    Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 31:895-902. 2013
  2. ncbi Failure patterns in patients with esophageal cancer treated with definitive chemoradiation
    James Welsh
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 118:2632-40. 2012
  3. ncbi Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study
    James Welsh
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 81:1336-42. 2011
  4. ncbi The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
    James W Welsh
    Departmentr of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA
    Radiat Oncol 4:69. 2009
  5. ncbi Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy
    James Welsh
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 81:91-6. 2011
  6. ncbi Esophageal cancer dose escalation using a simultaneous integrated boost technique
    James Welsh
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 82:468-74. 2012
  7. ncbi Update: modern approaches to the treatment of localized esophageal cancer
    James Welsh
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 13:157-67. 2011
  8. ncbi Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly
    Shervin M Shirvani
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Int J Radiat Oncol Biol Phys 84:1060-70. 2012
  9. ncbi Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy
    Akihiro Suzuki
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncology 82:108-13. 2012
  10. ncbi Aortic dose constraints when reirradiating thoracic tumors
    Jaden D Evans
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States Texas Tech University Health Sciences Center School of Medicine, Lubbock, United States
    Radiother Oncol 106:327-32. 2013

Collaborators

Detail Information

Publications12

  1. ncbi Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer
    James W Welsh
    Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 31:895-902. 2013
    ..Additional end points were radiologic response and safety...
  2. ncbi Failure patterns in patients with esophageal cancer treated with definitive chemoradiation
    James Welsh
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 118:2632-40. 2012
    ..Little is known about the failure pattern based on modern-day radiation treatment volumes. We hypothesized that most local failures would be within the gross tumor volume (GTV), where the bulk of the tumor burden resides...
  3. ncbi Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study
    James Welsh
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 81:1336-42. 2011
    ..In the present study, we compared the dosimetric parameters for photon IMRT with that for intensity-modulated proton therapy (IMPT) for unresectable, locally advanced, distal esophageal cancer...
  4. ncbi The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
    James W Welsh
    Departmentr of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA
    Radiat Oncol 4:69. 2009
    ..We hypothesized that inhibiting c-Met would decrease this protection and thus sensitize resistant tumor cells to the effects of radiation therapy...
  5. ncbi Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy
    James Welsh
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 81:91-6. 2011
    ..We attempted here to identify dose-volume parameters that predict chest wall toxicity (pain and skin reactions) in patients receiving thoracic SBRT...
  6. ncbi Esophageal cancer dose escalation using a simultaneous integrated boost technique
    James Welsh
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 82:468-74. 2012
    ..We performed a planning study to evaluate if a simultaneous integrated boost (SIB) technique could selectively deliver a boost dose of radiation to the GTV in patients with esophageal cancer...
  7. ncbi Update: modern approaches to the treatment of localized esophageal cancer
    James Welsh
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 13:157-67. 2011
    ....
  8. ncbi Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly
    Shervin M Shirvani
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Int J Radiat Oncol Biol Phys 84:1060-70. 2012
    ....
  9. ncbi Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy
    Akihiro Suzuki
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncology 82:108-13. 2012
    ..We used a number of clinical pre- and post-treatment parameters to establish two nomograms: for overall survival (OS) and relapse-free survival (RFS)...
  10. ncbi Aortic dose constraints when reirradiating thoracic tumors
    Jaden D Evans
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States Texas Tech University Health Sciences Center School of Medicine, Lubbock, United States
    Radiother Oncol 106:327-32. 2013
    ..Improved radiation delivery and planning has allowed, in some instances, for the retreatment of thoracic tumors. We investigated the dose limits of the aorta wherein grade 5 aortic toxicity was observed after reirradiation of lung tumors...
  11. ncbi Exploring the feasibility of dose escalation positron emission tomography-positive disease with intensity-modulated radiation therapy and the effects on normal tissue structures for thoracic malignancies
    Lehendrick M Turner
    The University of Texas M D Anderson Cancer Center School of Health Professions, Medical Dosimetry Program, Houston, TX, USA
    Med Dosim 36:383-8. 2011
    ..The target's mean doses were significantly increased based on p-value analysis, while the normal tissue structures were not significantly changed...
  12. ncbi Rad51 protein expression and survival in patients with glioblastoma multiforme
    James W Welsh
    Department of Radiation Oncology, University of Arizona College of Medicine, Tucson, AZ, USA
    Int J Radiat Oncol Biol Phys 74:1251-5. 2009
    ..We hypothesized that Rad51 might contribute to GBM's apparent radioresistance and consequently influence survival...